Gefitinib, a small molecular EGFR inhibitor, is approved for the treatment of patients with non-small cell lung cancer (NSCLC) after failure of both platinum-based or docetaxel chemotherapies [22,23]. Here, EGFR is linked to non-small cell lung carcinoma.